SCHEMBL6484440

SCHEMBL6484440

CCCN(CCC)c1ccc(CCCc2cccc(Nc3ccccc3C(=O)O)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.48
CTSV O60911 2/20 0.48
CTSL P07711 2/20 0.48
MEN1 O00255 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SIRT2 Q8IXJ6 4/20 0.47
PLK1 P53350 4/20 0.47
PLK3 Q9H4B4 3/20 0.45
TAS2R14 Q9NYV8 2/20 0.44
RORC P51449 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
FABP4 P15090 1/20 0.43
TRPA1 O75762 1/20 0.42
TRPM2 O94759 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474928 0.92 SIRT1 (0.50) SIRT1CTSVCTSLMEN1RECQL
SCHEMBL6482938 0.90 MEN1 (0.53) CTSVCTSLMEN1RECQLBLM
SCHEMBL6476496 0.90 MEN1 (0.54) CTSVCTSLMEN1RECQLBLM
SCHEMBL27560781 0.86 MEN1 (0.58) CTSVCTSLMEN1RECQLBLM
SCHEMBL27581469 0.85 MEN1 (0.58) SIRT1CTSVCTSLMEN1RECQL
SCHEMBL6486359 0.85 PLK1 (0.53) MEN1RECQLBLMKMT2ATDP1
Hydrochloric Acid SCHEMBL6475141 0.85 MEN1 (0.57) CTSVCTSLMEN1RECQLBLM
SCHEMBL6474896 0.84 MEN1 (0.53) CTSVCTSLMEN1RECQLBLM
Hydrochloric Acid SCHEMBL6482984 0.84 MEN1 (0.57) SIRT1CTSVCTSLMEN1RECQL
SCHEMBL6482447 0.83 MEN1 (0.53) SIRT1CTSVCTSLMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 SIRT1 1765/4885CTSV 2743/4885CTSL 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.